These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24622699)

  • 21. Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?
    Sohani ZN; Li L; Sun X
    Diabetes Res Clin Pract; 2016 Jul; 117():28-31. PubMed ID: 27329019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database.
    Soranna D; Bosetti C; Casula M; Tragni E; Catapano AL; Vecchia CL; Merlino L; Corrao G
    Diabetes Res Clin Pract; 2015 May; 108(2):243-9. PubMed ID: 25748827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incretin-based therapies and pancreatitis risk: myth or reality.
    Pappachan JM
    Endocrine; 2015 Mar; 48(2):360-2. PubMed ID: 25433430
    [No Abstract]   [Full Text] [Related]  

  • 24. Do incretin-based therapies cause acute pancreatitis?
    Olansky L
    J Diabetes Sci Technol; 2010 Jan; 4(1):228-9. PubMed ID: 20167189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 27. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
    Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
    Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Incretin-based therapy in type 2 diabetes does not increase the risk of hospitalization for heart failure].
    Steurer J
    Praxis (Bern 1994); 2016 Jun; 105(13):785-6. PubMed ID: 27329712
    [No Abstract]   [Full Text] [Related]  

  • 29. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.
    Giorda CB; Sacerdote C; Nada E; Marafetti L; Baldi I; Gnavi R
    Endocrine; 2015 Mar; 48(2):461-71. PubMed ID: 25146552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretins and pancreatitis--what happens next? A personal viewpoint.
    Robson J
    Diabet Med; 2013 Oct; 30(10):1156-9. PubMed ID: 24073726
    [No Abstract]   [Full Text] [Related]  

  • 31. The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis--what happens next? A personal viewpoint.
    Ryder RE; Sen Gupta P; Thong KY;
    Diabet Med; 2013 Dec; 30(12):1510-1. PubMed ID: 24117729
    [No Abstract]   [Full Text] [Related]  

  • 32. Incretin-based therapy for type 2 diabetes: A real class effect?
    Savarese G; Lund LH; Rosano GMC
    Int J Cardiol; 2017 Jan; 227():141-142. PubMed ID: 27866064
    [No Abstract]   [Full Text] [Related]  

  • 33. Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
    Lamont BJ; Andrikopoulos S
    J Endocrinol; 2014 Apr; 221(1):T43-61. PubMed ID: 24424288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!
    Nauck MA; Meier JJ
    J Diabetes Sci Technol; 2014 Jul; 8(4):895-7. PubMed ID: 24876434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Welcome reassurance about GLP-1 drugs--but they are still young and not fully grown.
    Riddle MC
    Diabetes Care; 2015 Feb; 38(2):183-5. PubMed ID: 25614687
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
    Wagenaar P
    Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
    [No Abstract]   [Full Text] [Related]  

  • 39. Incretins and risk of neoplasia.
    Halfdanarson TR; Pannala R
    BMJ; 2013 Jun; 346():f3750. PubMed ID: 23751908
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.